Illumina Q4 Revenues Rise 45 Percent on Sequencing, Array Growth

Officials attributed the firm's Q4 performance to demand for its next-generation sequencing products as well as "solid year-over-year growth" in its microarray business.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.